Claims for Patent: 9,700,597
✉ Email this page to a colleague
Summary for Patent: 9,700,597
Title: | Methods of treating cognitive impairment |
Abstract: | The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment. |
Inventor(s): | Potter; Huntington (Denver, CO), Boyd; Timothy (Aurora, CO), Jim; Heather Sevey Lawrence (Tampa, FL) |
Assignee: | UNIVERSITY OF SOUTH FLORIDA (Tampa, FL) H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, FL) |
Application Number: | 14/730,485 |
Patent Claims: | 1. A method for improving cognition in a person or animal receiving or that has received chemotherapy or radiation exposure or treatment for the treatment of cancer, wherein
improvements in cognition are characterized by improvements in memory, attention, concentration, and/or executive function, said method comprising administering to the person or animal that is receiving or that has received chemotherapy or radiation
exposure or treatment for the treatment of cancer an effective amount of an inflammatory mediator(s), or a composition comprising said inflammatory mediator(s), wherein said inflammatory mediator is granulocyte/macrophage colony-stimulating factor
(GM-CSF), or granulocyte colony-stimulating factor (G-CSF), or an analog of said inflammatory mediator, wherein the analog of GM-CSF is sargramostim and wherein the analog of G-CSF is filgrastim or pegfilgrastim, and wherein the cognition of the person
or animal after administration of said inflammatory mediator or composition is improved relative to the cognition of the person or animal prior to administration of said inflammatory mediator or composition.
2. The method of claim 1, wherein said inflammatory mediator is administered intracranially. 3. The method of claim 1, wherein said inflammatory mediator is administered by intracranial infusion. 4. The method of claim 1, wherein said inflammatory mediator is administered to a non-neural cell or tissue. 5. The method of claim 1, wherein said method further comprises evaluating the person or animal for cognitive function prior to treatment. 6. The method of claim 1, wherein said composition comprises a pharmaceutically acceptable carrier, diluent, or solute. 7. The method of claim 1, wherein said method further comprises administering Darbepoetin and/or erythropoietin (EPO) to the person or animal. 8. The method of claim 1, where said GM-CSF is human GM-CSF. 9. The method of claim 1, wherein the cancer is multiple myeloma or non-Hodgkin's lymphoma. 10. The method of claim 1, wherein the person or animal received hematopoietic cell transplantation (HCT). 11. The method of claim 1, wherein said inflammatory mediator is administered orally, intravenously, intramuscularly, intraperitoneally, subcutaneously, or intranasally. 12. The method of claim 1, wherein the cancer is acute myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, breast carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloproliferative neoplasm, Hodgkin's lymphoma, or aplastic anemia. 13. The method of claim 1, where said G-CSF is human G-CSF. |
Details for Patent 9,700,597
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 02/20/1991 | ⤷ Try a Trial | 2028-08-05 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 06/28/2000 | ⤷ Try a Trial | 2028-08-05 |
Partner Therapeutics, Inc. | LEUKINE | sargramostim | For Injection | 103362 | 03/05/1991 | ⤷ Try a Trial | 2028-08-05 |
Partner Therapeutics, Inc. | LEUKINE | sargramostim | Injection | 103362 | 03/05/1991 | ⤷ Try a Trial | 2028-08-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.